

# Hok Pan Yuen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2987415/publications.pdf>

Version: 2024-02-01

25  
papers

4,834  
citations

471371

17  
h-index

580701

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

3291  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States. Australian and New Zealand Journal of Psychiatry, 2005, 39, 964-971.  | 1.3 | 1,677     |
| 2  | Psychosis prediction: 12-month follow up of a high-risk (â€œprodromalâ€) group. Schizophrenia Research, 2003, 60, 21-32.   | 1.1 | 981       |
| 3  | Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research, 2004, 67, 131-142.  | 1.1 | 673       |
| 4  | Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk?. Schizophrenia Bulletin, 2007, 33, 673-681.  | 2.3 | 376       |
| 5  | Long-term Follow-up of a Group at Ultra High Risk (â€œProdromalâ€) for Psychosis. JAMA Psychiatry, 2013, 70, 793.  | 6.0 | 373       |
| 6  | Effect of Î‰-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. JAMA Psychiatry, 2017, 74, 19.   | 6.0 | 216       |
| 7  | Declining transition rates to psychotic disorder in â€œultra-high riskâ€ clients: Investigation of a dilution effect. Schizophrenia Research, 2016, 170, 130-136.  | 1.1 | 87        |
| 8  | NEURAPROâ€™ study protocol: a multicentre randomized controlled trial of omegaâ€™3 fatty acids and cognitiveâ€™behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Microbial Biotechnology, 2017, 11, 418-428.   | 0.9 | 55        |
| 9  | Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Microbial Biotechnology, 2018, 12, 292-306.   | 0.9 | 52        |
| 10 | Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2019, 206, 67-74.   | 1.1 | 46        |
| 11 | Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. Schizophrenia Bulletin Open, 2020, 1, .  | 0.9 | 45        |
| 12 | Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study. Neuropsychopharmacology, 2021, 46, 1494-1501.  | 2.8 | 44        |
| 13 | Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach. Frontiers in Psychiatry, 2020, 11, 553578.  | 1.3 | 30        |
| 14 | Longitudinal Cognitive Performance in Individuals at Ultrahigh Risk for Psychosis: A 10-year Follow-up. Schizophrenia Bulletin, 2019, 45, 1101-1111.   | 2.3 | 27        |
| 15 | Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. Schizophrenia Research, 2020, 226, 44-51.   | 1.1 | 27        |
| 16 | Performance of joint modelling of time-to-event data with time-dependent predictors: an assessment based on transition to psychosis data. PeerJ, 2016, 4, e2582.   | 0.9 | 25        |
| 17 | A new method for analysing transition to psychosis: Joint modelling of timeâ€™toâ€™event outcome with timeâ€™dependent predictors. International Journal of Methods in Psychiatric Research, 2018, 27, .   | 1.1 | 19        |
| 18 | Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for firstâ€™episode psychosis with lowâ€™risk of selfâ€™harm or aggression. Study protocol and baseline characteristics of participants. Microbial Biotechnology, 2019, 13, 953-960. | 0.9 | 19        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Dynamic prediction of transition to psychosis using joint modelling. Schizophrenia Research, 2018, 202, 333-340.  | 1.1 | 18        |
| 20 | Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. Microbial Biotechnology, 2021, 15, 642-651.   | 0.9 | 11        |
| 21 | Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. Microbial Biotechnology, 2021, 15, 874-881.  | 0.9 | 10        |
| 22 | Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2020, 218, 48-54. | 1.1 | 8         |
| 23 | Cognitive ability and metabolic physical health in first-episode psychosis. Schizophrenia Research: Cognition, 2021, 24, 100194.  | 0.7 | 5         |
| 24 | Dynamic prediction systems of transition to psychosis using joint modelling: extensions to the base system. Schizophrenia Research, 2020, 216, 207-212.   | 1.1 | 3         |
| 25 | Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. Schizophrenia Bulletin Open, 2022, 3, .   | 0.9 | 2         |